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Regulatory T cells (Tregs) play an important role in immunoregulation and have been 
shown in animal models to promote transplantation tolerance and curb autoimmunity 
following their adoptive transfer. The safety and potential therapeutic efficacy of these 
cells has already been reported in Phase I trials of bone-marrow transplantation and type 
I diabetes, the success of which has motivated the broadened application of these cells 
in solid-organ transplantation. Despite major advances in the clinical translation of these 
cells, there are still key questions to be addressed to ensure that Tregs attest their reputa-
tion as ideal candidates for tolerance induction. In this review, we will discuss the unique 
traits of Tregs that have attracted such fame in the arena of tolerance induction. We will 
outline the protocols used for their ex vivo expansion and discuss the future directions 
of Treg cell therapy. In this regard, we will review the concept of Treg heterogeneity, the 
desire to isolate and expand a functionally superior Treg population and report on the 
effect of differing culture conditions. The relevance of Treg migratory capacity will also be 
discussed together with methods of in vivo visualization of the infused cells. Moreover, we 
will highlight key advances in the identification and expansion of antigen-specific Tregs 
and discuss their significance for cell therapy application. We will also summarize the 
clinical parameters that are of importance, alongside cell manufacture, from the choice of 
immunosuppression regimens to the number of injections in order to direct the success 
of future efficacy trials of Treg cell therapy. Years of research in the field of tolerance have 
seen an accumulation of knowledge and expertise in the field of Treg biology. This perpet-
ual progression has been the driving force behind the many successes to date and has 
put us now within touching distance of our ultimate success, immunological tolerance.
Keywords: tregs, tolerance, transplantation, cellular therapy, clinical trials
introduction
Improvements in surgical techniques and the institution of T-cell directed immunosuppressive 
agents in the clinical transplantation of solid organs have seen remarkable advances now form-
ing part of a well-established treatment for end-stage failure of several major organs. However, 
despite vast improvements in short-term survival rates, long-term graft survival remains poor 
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owing to episodes of chronic rejection and the relative toxicity 
associated with life-long immunosuppression (1). The constant 
proportion of transplanted organs lost each year, necessitating 
re-transplantation, in a climate of donor organ shortage, places 
further strain on an already saturated transplant waiting list. 
With this in mind, the current standing of immunosuppression 
in transplantation is far from ideal. As such, the ultimate goal fol-
lowing transplantation is to induce immunological tolerance by 
“re-educating” the host’s immune response, permitting allograft 
acceptance without the need for pharmacological immunosup-
pression, thus ensuring long-term graft survival and abolishing 
drug-toxicity simultaneously.
The proposal of a distinct subset of T cells able to suppress 
immune responses was first put forward in the 1970s, which 
led to scientists around the world scouring for the existence of 
these “suppressor” T cells (2). It was not till the mid 90s when 
a thymic-derived lymphocytic population, coined regulatory T 
cells (Tregs), were defined. Subsequent years saw accumulating 
evidence certifying the therapeutic potential of these cells in 
preventing alloimmunity, explored in animal models, presenting 
Tregs as ideal candidates for use in tolerance-promoting proto-
cols. Such an evolution in the field has since provided the impetus 
for the development of robust Treg manufacturing plans for the 
isolation and expansion of a functional and stable Treg product.
Here, we dissect the characterization and operation of these 
cells and outline strategies employed for their isolation and ex 
vivo expansion, which in turn have inspired their therapeutic 
application in bone-marrow transplantation (BMT), type-1 
diabetes and, more recently, solid-organ transplantation.
Regulatory T cells
Tregs constitute approximately 1–3% of circulating CD4+ T cells 
in the periphery (3) and have been characterized by the high 
and stable expression of surface interleukin-2 receptor α chain 
(IL-2Rα, CD25hi) (4).
Initially, Tregs were conventionally characterized in accord-
ance with their site of differentiation, namely thymus-derived 
natural Tregs (tTregs) and peripherally induced Tregs (pTregs), 
alongside their in  vitro counterparts, commonly referred to as 
iTregs (5) (Figure 1). tTregs, from here on referred to as Tregs, 
are spawned from negatively selected thymocytes, whereas the 
conditions favoring the generation of pTregs include suboptimal 
dendritic cell (DC) activation, sub-immunogenic doses of ago-
nist peptide, mucosal administration of peptide, and antigenic 
encounter in a pro-tolerogenic environment, such as in the 
presence of interleukin-10 (IL-10), transforming growth factor-β 
(TGF-β), interleukin-2 (IL-2), and retinoic acid (6).
There are at least two well-defined populations of pTregs; Th3, 
first identified from their role in oral tolerance through the secre-
tion of TGF-β (7), and Tr1, characterized on the basis of their role 
in preventing autoimmune colitis (8) and their ability to secrete 
large amounts of IL-10 (9, 10). As such, pTregs are implicated 
in the induction of oral and gut tolerance (11) and generated in 
chronically inflamed and transplanted tissues (12).
Of note, the phenotypic distinction of thymic and peripherally 
derived Tregs has not been clearly established, posing challenges 
in classifying the definitive proportions of these two subsets in 
secondary lymphoid organs and non-lymphoid tissues alike. In 
mice, neuropilin (Nrp-1) expressed on tTregs can differentiate 
these cells from their peripherally derived counterparts, which do 
not express this molecule (13, 14). However, this distinction does 
not hold true for human Tregs.
While Tregs have been crudely accrued into these populations, 
even within these factions, Tregs still exist in a highly organized, 
heterogeneous state. Various different surface and intracellular 
immunological markers have been studied, defining Tregs based 
on their functional characteristics, migration, and lineage 
plasticity.
In line with this, further characterization and understanding 
of Treg cell biology came from the discovery of FOXP3, an intra-
cellular transcription factor known to play a crucial role in the 
development and function of Tregs in a highly specific manner 
(15). Rare mutations of the FOXP3 gene have been linked with 
the development of immune dysregulation, polyendocrinopathy, 
enteropathy, X-linked syndrome (IPEX), leading to organ-specific 
autoimmune diseases including insulin-dependent diabetes mel-
litus and various hematological disorders (15). Furthermore, the 
importance of FOXP3 in the safeguarding of Treg phenotype and 
function has been reiterated in studies where a loss/diminution 
of FOXP3 expression in Tregs has been shown to affect the com-
petency of these cells acquiring certain effector T cell properties, 
including production of cytokines, such as IL-2, IL-4, IL-17, and 
IFN-γ (16).
Additionally, while FOXP3 has been termed a “master control 
gene,” specifically with regards to Treg development, its expres-
sion is not uniformly homogenous. In contrast to mice, where 
foxp3 is expressed exclusively on Tregs, in humans, increasing 
evidence has shown that effector cells can transiently express 
FOXP3, with no associated regulatory activity. Based on such 
studies and taking also into account its intracellular expression, 
this marker in isolation cannot be considered to be entirely suf-
ficient in demarcating human Tregs (17).
However, reports have commented on the inverse correla-
tion between the expression of the α-chain of the IL-7 receptor, 
CD127, and FOXP3 expression with respect to Treg functional 
suppressive capabilities (18). As such, the combination of CD25, 
FOXP3, and CD127 are considered to be the most stringent 
markers in defining Tregs in the research setting.
Additionally, following the recent discovery of naïve suppres-
sive FOXP3+ cells (CD45RA+) present in the cord blood and in 
adult blood, and FOXP3+ cells, which express a memory-like 
phenotype (CD45RA−), it has been proposed that three phe-
notypically and functionally distinct sub-populations based on 
the differential expression of CD25, FOXP3, and CD45RA can 
be defined: population I (CD25++FOXP3+CD45RA+) classified 
as resting Tregs, population II (CD25+++FOXP3hiCD45RA−) 
termed activated Tregs, and population III (CD25++FOXP3+
CD45RA−), which was proposed to consist of non-suppressive 
FOXP3lo cells (19). Further analysis of the three populations by 
Miyara et al. revealed that population I and II were both able to 
suppress in vitro with population II displaying a higher expres-
sion of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), 
a mechanism proposed for Treg suppressor function (Figure 2), 
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yet were more prone to apoptosis following exertion of their 
suppressive function. Population III, however, was shown to be 
non-suppressive in vitro (19).
Demarcation of these three populations of Tregs was also able 
to depict the differentiation dynamics of FOXP3+ Tregs in vivo. 
Resting Tregs were found to upregulate their FOXP3 expression, 
following stimulation, and mature to terminally differentiated 
activated Tregs thus replenishing the apoptotic pool of activated 
Tregs. Miyara et al. suggested that population III had the greatest 
potential to differentiate into inflammatory Th17 cells, inferred 
from their relative IL-17 production following cytokine stimula-
tion. The three comparative populations are found in different 
proportions in certain biological environments and their analysis 
can prove to be instrumental in identifying the immunological 
pathophysiology of disease and the optimal Treg subpopulation 
for cell therapeutic application.
It should, however, also be noted that the definitive functional 
characteristics of population III are controversial. Booth et  al. 
and data from our laboratory indicated that both CD45RO+ 
and CD45RA+ Treg subsets are equally suppressive, popula-
tion III representing a bona fide Treg subpopulation, bearing T 
cell memory markers (20). Moreover, we and others, have also 
reported the expression of CD161, a member of the killer cell 
lectin-like receptor subfamily B, on a subpopulation of human 
Tregs in population III, that produce IL-17 upon in vitro activation 
FiGURe 1 | Regulatory T cell populations. Selection of naïve CD4+ T cells 
and natural Tregs occurs in the thymus. Thymic-derived natural Tregs (tTregs), 
the main focus of this review, have been reported to express a variety of 
activation and functional markers as depicted in the diagram. Naïve CD4+ T 
cells, subsequently, can differentiate into several different T cell subsets: Th1, 
Th2, Th17, induced Tregs, in the periphery, all heralding distinct immunological 
roles. These differentiation programs are controlled by different cytokines and 
each separate CD4+ T cell subset can be identified from their lineage-specific 
transcription factors responsible for the regulation and maintenance of their 
individual functions; T-bet (Th1 cells), GATA3 (Th2 cells), RORγt (Th17 cells), 
FOXP3 (Tregs). Each subset has its own immunological role in vivo: Th1 cells 
secrete IFNγ, controlling immunity to foreign pathogens. Th2 cells produce 
various cytokines including: IL-4, IL-5, IL-13, IL-10, which are primarily 
involved in promoting humoral immunity, protecting against infection. Th17 
cells produce predominantly the inflammatory cytokine, IL-17, and play an 
important role in controlling pathogens especially at environmental surfaces 
and the cytokine, IL-22. Despite the apparent terminal differentiation of all 
these cells, they cannot be considered to be committed to one cell fate. 
Lineage plasticity following differentiation is depicted by the dotted arrows 
between the cells. This diagram is far from comprehensive; it is most likely that 
the future will see various changes and additions to this diagram concerning 
the differentiation of CD4+ T cells. In vitro generation of Tregs in the presence 
of IL-2 and TGF-β polarizing conditions leads to the development of iTregs. 
Abbreviations: APC, antigen presenting cells; CD, cluster of differentiation; 
CTLA-4, cytotoxic T-lymphocyte-associated protein 4; FOXP3, forkhead 
Box P3; IFN, interferon; IL, interleukin; IRF, interferon regulatory factor; iTreg, 
induced Treg; nTreg, natural Treg; pTreg, peripheral Treg; RORγt, retinoid 
related orphan receptor γ; T-bet, T box transcription factor; TCR, T cell 
receptor; TGF-β, transforming growth factor-β; Th, T helper cell; Treg, 
regulatory T cell.
in the presence of IL-1β, but not IL-6. In addition, evidence has 
also supported the suppressive capacity of these cells (21, 22).
Above, we have outlined some of the key Treg markers of 
which are pertinent when considering the isolation of these cells 
for clinical application. However, one must be wary that the array 
of markers outlined in this review is far from exhaustive. For a 
comprehensive review of Treg markers, the reader is directed to 
Schmetterer et al. (23) and Povoleri et al. (6).
The mechanisms of Treg suppression still remain elusive. 
In vitro studies have demonstrated that the immunosuppres-
sive qualities native to Tregs manifest through a variety of 
mechanisms, namely, modulation of APC maturation and 
function (24–26), anti-inflammatory cytokine production 
(27–30), induction of apoptosis in target cells (31, 32), and 
disruption of metabolic pathways (33, 34) (Figure 2).
Regulatory T Cells in Transplantation; 
Lessons Learnt From Pre-Clinical Data
The current paradigm hypothesizes that immune tolerance in 
transplantation is determined by a balance of Tregs over T effector 
cells. With this phenomenon in mind, the therapeutic potential of 
inducing and expanding Tregs directly in vivo or infusing autolo-
gous ex vivo-expanded Tregs represents a promising approach in 
the induction and maintenance of transplantation tolerance.
FiGURe 2 | Mechanisms of Treg suppression. (A) Disruption of metabolic 
pathways. The ectoenzymes CD39 and CD73, expressed on Tregs, result in 
the metabolism of ATP to AMP and in turn producing the immunoregulatory 
purine, adenosine. Tregs have also been found to express high levels of 
intracellular cAMP. This is transferred to T effector cells through gap 
junctions, which leads to the upregulation of ICER and in turn the inhibition of 
NFAT and Il-2 transcription leading to apoptosis by IL-2 deprivation. 
(B) Modulation of APC maturation and function. The interaction of CTLA-4 on 
Tregs with its ligand CD80/86 on APCs delivers a negative signal for T cell 
activation. CTLA-4’s mechanism of action is varied including the capture of 
its APC-expressed ligands and subsequent trans-endocytosis and also the 
upregulation of IDO and the generation of kynurenines. (C) Anti-inflammatory 
cytokine production. The secretion of anti-inflammatory cytokines, such as 
IL-10, IL-35, and TGF-β, has been linked with inhibition of T cell activation 
in vivo. (D) Induction of apoptosis. Tregs have the capacity to directly induce 
apoptosis via granzyme A/B and perforin, TRAIL, the Fas/Fas-ligand 
pathway, the galectin-9/TIM-3 pathway, or the production of galectin-1. 
Abbreviations: APC, antigen presenting cell; AMP, adenosine 
monophosphate; ATP, adenosine triphosphate; cAMP, cyclic adenosine 
monophosphate; CD, cluster differentiation; CTLA-4-cytotoxic T lymphocyte 
antigen-4; DC, dendritic cells; ICER, inducible cAMP early repressor, IDO, 
indoleamine 2,3-dioxygenase IL, interleukin; NFAT, nuclear factor of activated 
T cells; TGF-β, transforming growth factor-β; TIM-3, T cell immunoglobulin 
and mucin domain-3; TRAIL, tumor necrosis factor-related apoptosis-
inducing ligand; Treg, regulatory T cells.
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Series of pre-clinical rodent models of skin and cardiac trans-
plantation demonstrated that Tregs present in the recipient at the 
time of transplantation are critical in the induction and mainte-
nance of tolerance [reviewed in Ref. (35)]. Additionally, mouse 
models of BMT further supported the importance of adoptive 
Treg therapy, whereby the transfer of freshly isolated Tregs 
together with the bone-marrow allograft resulted in amelioration 
of graft versus host disease (GvHD) and facilitated engraftment 
(36, 37).
Moreover, adoptive transfer of Tregs has been shown to pre-
vent rejection in other murine models of transplantation, such as 
pancreatic islets (38).
An issue for consideration in Treg cell therapy in transplan-
tation is the relevance of Treg allospecificity with the selective 
advantage that the immunomodulatory function of these cells 
would be concentrated at the site of alloantigen and immune 
activation (39). An additional advantage of alloantigen-specific 
cellular therapy is that undesirable pan-suppression, resulting in 
increased risk of infections and cancers, is less likely to occur.
Although the indirect pathway has been implicated in acute 
graft rejection (40), its influence has been more closely associated 
with chronic allograft rejection (41). Indeed, much evidence sug-
gests that for tolerance to occur, this is the pathway that needs to 
be regulated and it is this pathway of allorecognition that is used 
by Tregs for immunoregulation (29, 41–44).
In agreement, we have shown that using Tregs with indirect 
pathway anti-donor allospecificity for a single MHC class I result 
in the induction of donor-specific transplantation tolerance in a 
murine skin transplant model following thymectomy and selec-
tive T cell depletion (45). However, in a later study, we reported 
that Treg lines specific for directly and indirectly presented 
alloantigens are needed to induce indefinite survival of MHC-
mismatched heart allografts, with Tregs with indirect allospeci-
ficity necessary to prevent chronic vasculopathy (46). Moreover, 
Joffre et  al. have provided additional evidence that Tregs with 
direct allospecificity alone cannot protect against chronic rejec-
tions (47) supporting the notion that Tregs with both specificities 
are necessary to control allograft rejection.
Additional support for the use of alloantigen-specific Tregs 
in the transplant setting has been made available by the use of 
currently available humanized mouse models of allotransplanta-
tion (48–52). These models are based on the reconstitution of 
immunodeficient mice with human immune cells. Our group 
has recently shown the efficacy of human Tregs with direct allo-
specificity in preventing alloimmune dermal tissue injury using 
a humanized mouse model of skin transplantation in which only 
T cells have engrafted (53). The general consensus throughout 
these studies concluded that donor antigen-specific Tregs are 
more effective as compared to polyclonal Tregs.
In addition to the evidence supporting the importance of 
antigen-specific Tregs in preventing solid-organ rejection, after 
BMT donor-specific Tregs have been shown to preserve graft 
versus tumor activity, while inhibiting GvHD (54). However, 
further studies in the context of GvHD have reported that the 
transfer of Tregs enriched for alloantigen-specificity showed only 
moderately improved efficacy when compared to polyclonal Treg 
cell populations (55). As such, phase I clinical trials, using poly-
clonal Tregs, following hematopoietic stem cell transplantation 
have been conducted (56–58).
Such adoptive transfer experiments in rodents, therefore, have 
informed and instigated efforts to harness the immunoregulatory 
properties of these cells in novel tolerance promoting strategies 
in the prevention of rejection after organ transplantation. Thus, 
“tipping the balance” in favor of regulation by directly applying 
ex vivo-expanded Tregs is a promising strategy. In the next sec-
tion, we will highlight the advances in the field in view of Treg 
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isolation and expansion, reviewing some of the challenges and 
progress to date as well as review the lessons learned from the 
clinical application of these cells.
Treg Manufacture for Clinical Application
Approaches for Treg isolation
The effective implementation of Treg therapy in transplantation 
is dependent on Treg manufacturing plans with protocols that are 
compliant with good manufacturing practice (GMP).
The clinical Treg selection protocol to date in the UK has been 
used by our group in the new Clinical Research Facility (CRF) 
at Guy’s Hospital and involves a combination of depletion of 
CD8+ cells and positive selection of CD25+ cells using the auto-
mated CliniMACS plus system (Miltenyi Biotec, Bisley, United 
Kingdom), which is centered around the concept of magnetic 
bead isolation. The major drawback with such a technique is 
that this process does not allow the selection of Tregs based 
on multiple parameters, an attractive prospect when trying to 
isolate a Treg population with the desired characteristics for cell 
therapeutic application.
Additionally, the lack of distinction of CD25hi cells, using this 
protocol, means that the isolation may include contaminating 
conventional activated T cells, explaining the reduced purity 
of this strategy for Treg isolation as compared to the use of the 
fluorescence-activated cell sorting (FACS) technique (59, 60).
Despite the CliniMACS system being the only currently 
available GMP compatible technology for the isolation of clinical 
grade Tregs in the UK, there is still much enthusiasm for clinical 
cell separation using FACS sorting. Although currently unclear as 
to which Treg subset provides the best therapeutic activity, GMP-
compliant FACS sorting will open up the possibility of isolating 
Treg subsets with potent suppressive function, specificity, and 
those that are epigenetically stable.
Two different combinations of markers have been proposed 
to be promising for the isolation of a pure Treg population. The 
first seeks to isolate CD4+CD25hi Tregs with the addition of an 
antibody to select for CD45RA+ cells and so eliminate antigen 
experienced or memory T cells (61). Moreover, this so-called 
naïve Treg population yields Tregs with a greater suppressive 
capacity than total CD25hi cells (62) and have the greatest expan-
sion potential (61).
Furthermore, it has been demonstrated that between the 
FOXP3 promoter and the first exon lies a stretch of highly con-
served, non-coding sequence that is differentially methylated in 
tTregs, pTregs, and T effectors (63, 64). This sequence, referred 
to as the Treg-specific demethylated (TSDR) region, is crucial at 
maintaining high FOXP3 expression in Tregs (65).
Additionally and in support of the isolation of the CD45RA+ 
Treg subset for cell therapy application, supplementary evidence 
report that after 3  weeks of in  vitro expansion, the CD45RA+ 
expanded Tregs remained demethylated at the TSDR region, 
confirming their stability during expansion (60, 62).
The importance of isolating and expanding a stable Treg popu-
lation becomes even more pertinent when considering Treg cell 
therapy in inflammatory/autoimmune conditions. Emerging data 
have highlighted that despite the strict government of FOXP3 
expression, Tregs can downregulate FOXP3 in the presence of 
inflammatory cytokines. In agreement, Yang et  al. have shown 
that exposure of Tregs to IL-6 and IL-1 in  vitro results in the 
expression of IL-17 (66). In  vivo, loss of FOXP3 has also been 
documented in the setting of autoimmune disease (67) fetal acute 
infections (68), TLR stimulation (69), and homeostatic prolifera-
tion (70).
Therefore, with evidence supporting the stability of 
CD4+CD25+CD45RA+ Tregs, we have recently advocated the 
isolation and expansion of these cells for cell therapeutic applica-
tion in the setting of inflammatory bowel disease (71).
Despite such studies in favor of CD45RA+ cells, one drawback 
is that the number of naïve Tregs decline in the peripheral blood 
with age (72) and hence isolation based on this approach may 
prove to be impractical.
The second approach still uses the fundamental CD4+CD25hi 
phenotype to isolate Tregs but also includes CD127 expression. 
The rationale placed on the foundation that in human Tregs, 
there is a reciprocal expression of CD127 and FOXP3 and thus 
CD127 provides a sortable surrogate marker for FOXP3+ Tregs 
(18). Moreover, two elegant studies (48, 50) support the in vivo 
superiority of the CD4+CD25+CD127lo Tregs in regulating allo-
reactivity compared to Tregs isolated based on the expression of 
CD4 and CD25 alone.
Such studies merely highlight the importance of multiparam-
eter separation of Tregs, using the FACS cell sorter. In this regard, 
the last few years have not only seen significant efforts made in 
obtaining the relevant regulatory approvals to integrate the FACS 
cell sorter into a clinical cell production process, but an immense 
progress in the technology to do so.
As such, a new era of clinical flow sorting has seen the recent 
introduction of a class of flow sorting devices, utilizing micro-
fluidic chips instead of the classical flow-in-air droplet sorters. 
Unlike traditional sorting, there is no high-pressure, shearing 
forces, or dilution by sheath fluid, resulting in a cell processing 
that may preserve cell function and viability. Additionally, cells 
are processed in closed systems, thus eliminating the risk of con-
tamination of the product during processing. Such a system, how-
ever, did not present itself without technical challenges including 
the initial slow sort speed. These have been overcome either by 
massive parallel sorting on a single microfluidic chip, such as in 
the Cytonome GigaSort System (Cytonome/ST, LLC, Boston, 
MA, USA) (73) or by the introduction of mechanical microvalves 
operating at high speed, such as the recently introduced MACS 
Quant Tyto (Miltenyi Biotec, Bergisch Gladbach, Germany).
Although not yet clinically approved, both machines are in 
principal designed for clinical cell separation processes and 
provide significant advantages allowing their integration into 
GMP-compliant production processes.
Polyclonal Treg expansion: Optimization of 
Current Culture Conditions
One of the obstacles in the implementation of clinical protocols 
for adoptive Treg cell therapy is their relative paucity in the 
circulation. This means that for cellular therapy, it will almost 
certainly be necessary to expand these cells ex vivo, to clinically 
relevant numbers, prior to their administration. It has already 
FiGURe 3 | immunological targets for immunosuppressive drugs in 
T cells. Drugs can affect specific molecular pathways and control gene 
expression to block alloactivation of T cell after transplantation and induce 
tolerance. Abbreviations: TCR, T-cell receptor; mTOR, mammalian target of 
rapamycin; MMF, mycophenolate mofetil; PI3K, phosphatidylinositol 3-kinase; 
IL-2R, interleukin-2 receptor; NFkB, nuclear factor κ-light-chain-enhancer of 
activated B cells; MAPK, mitogen-activated protein kinase; NFAT, nuclear factor 
of activated T-cells.
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been demonstrated that Tregs can be readily expanded using 
anti-CD3/CD28-coated beads, supplemented with IL-2 (60, 
74). However, under these circumstances, effector cells have the 
potential to proliferate vigorously, posing a major problem for 
MACS-purified CD4+CD25+ Tregs, as they are often contami-
nated with CD25+FOXP3- cells. Thus, this not only puts under 
question the potential safety of the final product but also the 
efficacy. As such, much effort has, therefore, focused on optimi-
zation of culture conditions to ensure the expansion of Tregs to 
achieve the necessary numbers yet limit the potential expansion 
of contaminant cells.
Rapamycin
This immunosuppressant mechanism of action involves the inhi-
bition of the mammalian target of rapamycin (mTOR), which is 
downstream of phosphatidylinositol 3-kinase (PI3K), a signaling 
molecule activated by CD28 or IL-2 receptor engagement in T 
cells (75) (Figure 3). Characteristically, IL-2 receptor engagement 
activates both PI3K-mTOR and Janus kinase-STAT pathways. 
However, biochemical analysis of IL-2 signaling in Tregs has 
shown that the PI3K–mTOR pathway is underactive, whereas 
the Janus Kinase–STAT pathway remains intact, suggesting that 
Tregs preferentially signal through the latter in turn conferring 
their resistance to mTOR inhibition (76). In agreement, genetic 
ablation and cellular experiments that demonstrate mTOR 
deficiency or the addition of rapamycin favor the growth and 
preserved function of Tregs (77, 78). Paralleling these in  vitro 
observations, it has been shown that rapamycin can potentiate the 
ability of Tregs to inhibit transplant arteriosclerosis in a human-
ized mouse system (79). Furthermore, in transplant patients, the 
use of rapamycin-based immunosuppression is also associated 
with an increased proportion of Tregs as compared to patients 
on calcineurin inhibitors (CNI) (80, 81). Thus, by favoring Treg 
survival and expansion and by preventing the outgrowth of 
contaminating effector T cells (76, 82), rapamycin ensures the 
selection of a pure Treg population.
Further research has not only confirmed the unique preferen-
tial preservation of Tregs by rapamycin but has also reported its 
role in ensuring Treg stability. Treatment of CD4+CD25hiFOXP3+ 
with rapamycin has been shown to inhibit the development of 
IL-17-producing cells and to maintain a stable Treg phenotype 
favoring the expansion of non-plastic Treg subsets, both in vitro 
and in  vivo (83–85). The mechanism by which this occurs is 
thought to involve alterations in the epigenetic profile allowing 
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for the active transcription of FOXP3 (84, 86, 87). These findings 
support the use of rapamycin in clinically applicable protocols for 
the expansion of human Tregs. We are currently testing the safety 
of Tregs expanded following this protocol in the CRF at Guy’s 
Hospital in two Phase I/II clinical trials: in kidney (ONE Study: 
NCT02129881) and liver (ThRIL: NCT02166177) transplant 
patients.
Retinoic Acid and Vitamin D
Despite recent advances in Treg biology, large-scale manufacture 
of these cells remains challenging in view of studies reporting 
that even highly pure Tregs lose FOXP3 expression over time. 
In line with this, a study by Hoffman et  al. further concluded 
a loss of FOXP3 expression by Tregs upon repeated anti-CD3/
CD28 stimulation in culture, in turn forfeiting their stability (62). 
As such, recent attention has been drawn to other approaches 
that ensure Treg stability in culture, an example including the 
supplementation of cultures with all-trans-retinoic acid (ATRA).
Of note, natural derivatives and metabolized products of 
vitamin A, such as β-carotene, retinol, retinal, isotetrinoin, 
ATRA, and 9-cis-Retinoic acid all have important roles in cell 
differentiation, growth, and apoptosis (88). ATRA is one of the 
most influential molecules on T cells and has been reported to 
affect T cell fate by contributing to Th1/Th17 as well as Treg dif-
ferentiation (89). In combination with TGF-β, ATRA has been 
shown to promote differentiation of naive murine and human 
T cells into Tregs (90–92) and, more recently, as a treatment to 
expand human Tregs and increase their function (84, 85, 93, 94). 
The molecular pathway by which ATRA favors the expansion 
of Tregs is not entirely clear, but it is thought to induce chro-
matin de-condensation recruiting histone acetyl-transferases 
and transcription machinery to the FOXP3 promoter (95, 96). 
Furthermore, experiments in animal models have shown that 
deletion of ATRA nuclear receptor results in significant loss of 
FOXP3 expression in Tregs, suggesting that ATRA may act to 
stabilize FOXP3 expression (97).
However, while the use of ATRA during Treg culture heralds 
the expansion of a highly suppressive Treg population for cell 
therapy (84, 85, 94), there are concurrently major concerns 
regarding its use, primarily since ATRA preferentially stimulates 
ex novo generation of iTregs, which as eluded to earlier, have 
an unstable genetic phenotype with their plasticity influenced 
in vivo by the inflammatory conditions (87). As a consequence, 
the regulatory phenotype induced in vitro may be easily reverted 
into a pro-inflammatory one upon in vivo administration (98).
Indeed, there is a dynamic relationship between the transcrip-
tion factors RORγT and FOXP3 in T cells that rules the balance 
between Th17 cells and Tregs. The competitive antagonism of 
these trans-acting factors is controlled by pathways downstream 
of either IL-2 (pro-Treg) or IL-1β/IL-6 signaling (pro-Th17) 
(98). For this reason, an intense inflammatory condition may 
fully override ATRA-mediated FOXP3 expression and revert a 
protective Treg preparation into a potentially harmful immune 
response (87, 98).
Another potential supplementary candidate in Treg expansion 
that has attracted much attention is Vitamin D, with growing evi-
dence supporting the immunomodulatory roles of this vitamin 
and its importance in the induction and maintenance of FOXP3+ 
Tregs in vivo. As such, studies have highlighted that serum con-
centrations of vitamin D positively correlate with the number and 
frequency of FOXP3+ Treg cells in the peripheral blood of patients 
(99–102). However, the mechanism by which vitamin D controls 
the generation/expansion of Tregs is not completely clear, with 
vitamin D concentrations playing differing roles (102, 103). It 
appears that high non-physiological concentration (10−6  M) of 
Vitamin D induces IL-10 production by CD4+ T cells, providing 
an explanation for the immune-modulating and Treg-promoting 
ability of these settings. Instead, at a more physiological con-
centration (10−7 M), vitamin D, together with TGF-β, favors the 
expansion of a highly suppressive FOXP3+ Tregs (102, 103).
The past few years have seen considerable effort focused on 
defining an optimal technique to isolate and expand Tregs from 
peripheral or cord blood. The studies outlined above highlight 
the future research directions in view of devising protocols that 
incorporate the use of these reagents in the expansion of an 
optimal Treg population for cell therapy application.
Alloantigen-Specific Regulatory T Cell 
expansion
In view of the wealth of animal data from our laboratory (49, 53, 
104) and others (47, 48, 55) in support of the importance of anti-
gen-specific Tregs in the setting of solid-organ transplantation, 
efforts have been directed at the generation of antigen-specific 
Tregs for cellular therapy in this setting.
To date, the generation and expansion of alloantigen-specific 
Tregs have proved to be an arduous task, in particular Tregs 
with indirect allospecificity. Recently, there have been advances 
in the propagation of Tregs with direct allospecificity using 
donor APCs, such as DCs and unfractionated peripheral blood 
mononuclear cells (PBMCs) (53, 105–107). In this regard and in 
a previous study, we screened human Tregs for activation mark-
ers following stimulation with allogeneic peripheral blood or 
dermal CD1c+ DCs (53). We subsequently defined the upregula-
tion of CD69 and CD71 by Tregs, at 3–5 days after activation, 
delineating the alloantigen-specific Tregs. Furthermore, we 
were able to comment on the suppressive superiority of these 
antigen-specific Tregs as compared to polyclonally expanded 
Tregs.
Moreover, recent reports have highlighted the effectiveness 
of CD40L-activated B cells in the induction and expansion of 
antigen-specific Tregs in  vitro (108–110). As such and in col-
laboration with colleagues at University of California (UCSF), 
we have shown the clinical grade manufacture of Tregs against 
allogeneic human leukocyte antigen (HLA) of the donor (104). 
Purified Tregs were stimulated ex vivo with CD40L-activated 
allogeneic B cells, followed by subsequent expansion using 
anti-CD3/anti-CD28-coated beads with the addition of IL-2. By 
employing this protocol, we were able to demonstrate not only the 
successful expansion (300- to 500-fold) but also the alloreactiv-
ity of the expanded Tregs against the donor antigen. We further 
demonstrated the antigen-specific suppressive function of the 
expanded Tregs in protecting against alloimmune-mediated 
skin damage in a humanized mouse model of transplantation. 
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The manufacture of Tregs, using this protocol, is currently being 
tested as part of a clinical trial at UCSF (NCT02188719).
An alternative approach has been to engineer Tregs with the 
ability to target specific antigens by expressing antigen-specific 
TCRs (111) or taking advantage of the growing field of Chimeric 
Antigen Receptors (CAR) (112). To date, most of the CAR studies 
have focused on tumor antigen-specific cytotoxic CD8+ T lym-
phocytes for the treatment of human cancers. However, several 
studies in animals suggest that CAR-expressing Tregs can be 
efficacious in preventing experimental autoimmune encephalitis 
(EAE) (113) or colitis (114). More recent work from our group 
has set out to investigate the efficacy of CAR-expressing Tregs in 
the setting of transplantation.
It is also pertinent to note that given the experimental evi-
dence detailing the synergy of direct and indirect Tregs in the 
setting of transplantation tolerance, considerable efforts have 
been concentrated on generating and expanding Tregs with indi-
rect allospecificity to further assist in this endeavor (115, 116). 
In contrast to the definitive selective expansion of Tregs with 
direct allospecificity from the existing repertoire, studies have 
demonstrated the difficulties in generating Tregs with indirect 
allospecificity using the same APCs used for the generation of 
Tregs with direct allospecificity. TCR-transduction was used by 
us to confer indirect allospecificity and we have demonstrated 
both in skin and heart transplants, the efficacy of Tregs with 
such a specificity. In addition, we have shown the advantage of 
conferring indirect alloreactivity during the expansion of direct 
alloreactive Tregs so as to generate Tregs with dual specificity, 
with promising results (111, 117).
Despite the on-going efforts to develop protocols for the 
manufacture and ex vivo expansion of allospecific Tregs, it is 
pertinent to note that our initial data highlighted that a highly 
pure population of Tregs was essential prior to their allospecific 
ex vivo expansion for this to be a success (104). As such and in 
view of the lack of GMP-compliant sorting technology in the 
UK, the application of antigen-specific Tregs in trials of Treg 
cell therapy in the UK have not been possible. However, with 
the upcoming installation of a GMP-compliant cell sorter into 
our facilities, efforts will be directed toward the generation of an 
optimal precursor population of antigen-specific Tregs for cel-
lular therapy in the near future.
Tregs Therapy in Solid-Organ 
Transplantation; Our experience to Date
The results of the trials to date have highlighted the favorable 
safety profile of freshly isolated and polyclonally expanded Tregs 
with varied reports of efficacy (56–58, 118) (Table 1). As a result, 
the prospects of Treg adoptive cell therapy are now widely recog-
nized with the information gleaned from these preliminary trials 
now guiding the clinical progression of these cells into the realms 
of organ transplantation.
In this regard, Yamashita et al. recently reported the first trial 
of donor alloantigen-specific Tregs in patients undergoing living 
donor liver transplantation (119). Here, iTregs were generated 
whereby recipient PBMCs were co-cultured with irradiated 
donor PBMCs in the presence of costimulatory blockade. 
Subsequent administration of 0.6–2.6 ×  109 iTregs in splenec-
tomized patients, concurrently receiving cyclophosphamide, 
was found to be not only safe in this setting but also enabled the 
withdrawal of immunosuppression in 6 out of the 10 patients 
recruited.
As alluded to earlier, the last few years has also seen the start 
of two clinical trials of Treg immunotherapy in solid-organ 
transplantation at King’s College London, the ONE Study 
(NCT02129881) and ThRIL (NCT02166177).
The ONE study is a multicenter Phase I/II study funded by 
the European Union FP7 program, investigating the safety of 
and potential efficacy of infusing ex vivo-expanded Tregs, among 
other regulatory cells. It is a dose escalation trial, designed to 
assess doses of 1, 3, 6, 10 × 106 Tregs/kg, injected at 5 days after 
transplantation so as to determine the maximum-tolerated dose. 
Of importance, patients, receiving the cell products at the differ-
ent centers will be on a similar immunosuppression regimen that 
includes prednisolone, tacrolimus, and mycophenolate mofetil 
(MMF). This will enable the direct comparison of transplant 
outcomes between the varied cell products tested as part of the 
ONE study.
Although the primary goal of the ONE study is to assess safety, 
the production feasibility of each of the cell products, at the varied 
doses, will also be assessed. In this regard, we have successfully 
produced the final product that to date has enabled three patients 
to be dosed at 1 × 106/kg, a further three patients at 3 × 106/kg 
and one patient at 6 × 106/kg. Five more patients remain to be 
dosed, two at 6 × 106 and three at 10 × 106. The final Treg product 
manufactured by us has been used to treat patients recruited at 
Oxford University and by Guy’s Hospital.
ThRIL (NCT02166177) is a combined Phase I/IIa clinical 
trial of Treg immunotherapy in the setting of liver transplanta-
tion where the safety, tolerability, and efficacy of 1 × 106/kg and 
4.5 × 106/kg of polyclonally expanded Tregs will be assessed with 
thymoglobulin and an mTOR-inhibitor-based immunosuppres-
sion regimen. ThRIL is currently in the recruitment stage and to 
date, we have dosed the first patient for this trial.
The near future will see the reporting of these trials, which 
will focus primarily on the safety of the injected cells, but 
will also speculate on their relative therapeutic efficacy, with 
reference to graft survival and supplementary biochemical and 
immunological markers of tolerance, in a bid to support larger 
Phase II/III studies. The success of such trials and the outlook 
of Treg therapy as an entirety will be defined from effective and 
informative clinical trial designs with adherence to hard efficacy 
end points. Thus, key issues will need to be addressed prior to 
the design of such trials including adjunct immunosuppressive 
regimens, the timing and number of injections, the dose of Tregs 
with the desired specificity, and the trafficking properties of the 
infused cells.
Tregs immunotherapy; Future Directions
immunosuppression and Tregs
Despite the initial confidence in adoptive Treg cell therapy as 
a self-sufficient entity, experimental data have shown that the 
efficacy of Treg therapy requires a favorable in vivo environment, 
A
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TABLe 1 | Clinical trials of Treg immunotherapy.
Clinical trial 
number 
investigators Setting Patients 
recruited
isolation Treg doses Study overview and results Reference
N/A Trzonkowski 
et al.
GVHD 
adult
2 FACS: 
CD4+CD25+CD127−
1 × 105 to 3 × 106/kg The first patient had chronic GvHD 2 years post BMT. After receiving 0.1 × 106/kg FACS 
purified ex vivo expanded Tregs from the donor, the patient was successfully withdrawn 
from immunosuppression without evidence of recurrence. The second patient had 
acute GvHD at 1-month post transplantation, treated with several infusions of expanded 
donor Tregs. Despite the initial and transitory improvement, the disease progressed and 
ultimately resulted in the patient’s death
(58)
NCT00602693 Brunstein, 
McMillan, 
Blazar (2010)
GvHD 
adult
23 CliniMACS: CD25+ 0.1, 0.3, 1, and 
3 × 106/kg
Tregs were isolated from a third party UCB graft and expanded polyclonally with anti-CD3/
CD28 coated beads and recombinant IL-2 over a period of 18 days. Patients received 
expanded Tregs at doses ranging from 1 × 105/kg to 30 × 105/kg. Targeted Treg dose 
was only achieved in 74% of cases. Compared with the 108 historical controls, there was 
a reduced incidence of grades II–IV acute GvHD (from 61–43%; p = 0.05), although the 
overall incidence of GvHD was not significantly different.
(56)
N/A Di Ianni et al. GvHD 
adult
28 CliniMACS: 
CD4+CD25+
2–4 × 106/kg Patients received donor Tregs without ex vivo expansion and donor effector T cells (Teff) 
without any other adjuvant immunosuppression. Different dose regimens were used, 
ranging from 5 × 105/kg Teffs with 2 × 106/kg Tregs to 2 × 106/kg Teffs with 4 × 106/kg 
Tregs. As two patients receiving the latter regimen developed acute GvHD, compared 
with none of the other patients, the dose of 1 × 106/kg Teffs with 2 × 106/kg Tregs 
was reported to be safe. Patients receiving Tregs demonstrated accelerated immune 
reconstitution, reduced CMV reactivation, and a lower incidence of tumor relapse and 
GvHD when compared to historical controls. Disappointing patient survival was reported 
with only 13 out of the 26 patients surviving
(57)
N/A Marek-
Trzonkowska 
et al.
Type-I 
diabetes 
children
12 FACS: 
CD4+CD25+CD127−
10–20 × 106/kg One year follow-up of 12 children with Type-I diabetes, treated with autologous-expanded 
ex vivo Tregs. Patients received either a single or double Treg infusion up to a total dose 
of 30 × 106/kg. The data supported the safety of the infused Tregs, with 8/12 treated 
patients requiring lower requirements of insulin, with two children completely insulin 
independent at 1 year
(118)
NCT01210664 Bluestone 
et al.
Type-I 
diabetes 
adult
14 FACS: 
CD4+CD25+CD127−
5 × 106–2.6 × 109/kg Infusion of 14 type-I diabetic patients with ex vivo-expanded Tregs (FACS purified and two 
rounds of anti-CD3/anti-CD28 stimulation). The first cohort of patients received 0.05 × 108 
cells, the second: 0.4 × 108 cells, the third: 3.2 × 108 cells, and the fourth: 2.6 × 109 cells. 
Enrolment and infusion is complete
Bluestone, in 
preparation
UCB, umbilical cord blood; GVHD, graft versus host disease; BMT, bone marrow transplantation.
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supporting both cell engraftment and the chance of inducing tol-
erance, such as transient host T cell depletion instituted following 
immunosuppressive treatments (120, 121).
As already discussed, the immunosuppression regimen for the 
ONE study includes the combination of CNI, tacrolimus together 
with prednisolone, and MMF. The main question that arises next 
is how this microenvironment will influence the Tregs in  vivo 
following adoptive transfer.
In this regard, studies have shown that the use of CNIs during 
adoptive Treg therapy may have an indirect impact on the survival 
and suppressive ability of Tregs in view of the strong dependence 
of these cells on the exogenous supply of IL-2 (122, 123).
In agreement, studies in animal models have reported that 
CNI treatment reduces FOXP3 expression in natural Tregs (123, 
124), diminishes the frequencies of CD4+CD25+FOXP3+ T 
cells (81), and fails to support the differentiation of the highly 
suppressive CD4+CD25+CD27+ Treg subset upon alloantigen 
stimulation (125). Studies in humans confirmed the negative 
effect of this treatment on Tregs, suggesting that the continuous 
CNI therapy is linked with progressive decline in Treg numbers 
(126). However, despite these major direct drawbacks on Tregs, 
it may be worth considering that CNI therapy may be still used 
to set up a favorable environment before the Treg infusion or at 
sub-therapeutic doses in combination with other drugs during 
Treg therapy. In this regard, Wang and collaborators showed that 
kidney transplanted recipients treated with MMF and low-dose 
tacrolimus had an induction of CD4+CD25+FOXP3+ Tregs that 
could expand in the periphery and accumulate in the allograft. 
Additionally, the in  vitro analysis of these cells confirmed the 
maintenance of their suppressive function (93).
On the other hand, the effects of MMF on Tregs have not been 
extensively analyzed and the few results reported are controversial. 
Data in literature support the idea that the influence of this drug 
on cell division may alter the expansion of antigen-specific Tregs 
and prevent the settlement of a long-term tolerance. In line with 
this notion, MMF administration in a murine model significantly 
inhibited the expansion of OVA-specific CD4+CD25+Foxp3+ 
Tregs after OVA immunization (127). Other studies, however, 
propose that MMF has no effect on Tregs or may facilitate the 
induction of a more tolerogenic environment (123).
Corticosteroids, such as dexamethasone and prednisolone, 
have been used for decades as basis for the treatment of inflam-
matory diseases and in patients post-organ transplantation. 
They regulate a wide spectrum of physiological processes and 
control not only inflammation but also carbohydrate and protein 
metabolism, fetal development, and behavior. For these reasons, 
despite their therapeutic efficacy, there are major drawbacks 
associated with the persistent use of glucocorticoids, such as 
osteoporosis and diabetes (128). However, in respect to the impact 
of these treatments on Treg therapy, many authors described 
positive effects of steroids on the maturation and expansion of 
Tregs. Glucocorticoids have been suggested to amplify the IL-2-
dependent expansion of FOXP3+CD4+CD25+ T cells in  vivo 
(129), increase FOXP3 expression by Tregs in patients affected 
by asthma (130), and restore the impaired suppressive func-
tion of Tregs in patients with relapsing multiple sclerosis (131). 
Furthermore, steroids may affect the inflammatory environment 
negatively controlling both Th1- and Th17-polarization in mice 
and humans (132–134).
This highlights the importance of strategies to tailor immuno-
suppressive therapy to ensure the in vivo survival of the injected 
Tregs or enhance their longevity in vivo. In this regard, the clinical 
protocol for ThRIL is based on a Treg-supportive immunosup-
pressive regimen including the use anti-thymocyte globulin 
(ATG), to induce lymphopenia with a preferential preservation 
of Tregs (135). Additionally, to limit memory T cell expansion 
post-ATG induction, patients are started on tacrolimus and 
prednisolone. One month prior to Treg infusion, in parallel with 
low-dose tacrolimus, the patients are given rapamycin, to pro-
mote selective Treg expansion in vivo (136). The intention behind 
this protocol: to create a tolerogenic milieu thus maximizing the 
potential efficacy of the exogenously administered Tregs through 
prolongation of their in  vivo survival. It is also reassuring that 
these cells will be injected in a “Treg nurturing” environment, 
centered on the inclusion of rapamycin.
Thus, tailoring the immunosuppressive regimen along with 
the administration of ex vivo-expanded Tregs may potentially 
maintain post-liver transplant tolerance, accomplishing the 
ultimate aim of Treg immunotherapy trials in this setting.
Stability and Longevity of the injected 
Cells and visualization In Vivo
For Treg cellular therapy to be a viable therapeutic avenue, two 
key factors need to be addressed. The first being that, following 
injection, the Tregs are stable in the graft and draining lymph 
nodes, irrespective of the local inflammatory environment fol-
lowing transplantation, and second, whether these cells are either 
long-lived or able to impart their tolerance to the host immune 
system.
As the function of Tregs is highly dependent on the constitu-
tively high expression of FOXP3 (137), many groups have sought 
to find ways to stabilize its expression. As discussed earlier, 
epigenetic modification of the FOXP3 locus has a major role 
in controlling FOXP3 transcription, with demethylation of key 
regions correlated with suppressive function and lineage stabil-
ity (138). In this regard, in  vitro treatment with demethylating 
agents, such as azacytidine, have shown to promote the stability of 
FOXP3 expression in Tregs, resulting in the potent ability of these 
treated cells to protect from GvHD (139). In addition, a recent 
Phase I trial has shown that patients with acute myeloid leukemia, 
treated with azacytidine immediately after allogeneic stem cell 
transplantation, had a higher proportion of Tregs as compared to 
time-matched controls (140).
FOXP3 levels are not only regulated through transcriptional 
control but also through post-translational modifications. In the 
context of transplantation, most work has focused on acetyla-
tion of lysine residues, which is known to stabilize the FOXP3 
protein (141, 142). It has been shown that inhibiting deacetyla-
tion with histone deacetylase (HDAC) inhibitors or genetically 
removing Sirtuin-1, a histone and protein deacetylase, leads to 
an improvement in Treg function and stability, ultimately leading 
to improved allograft survival (143). Thus, future directions of 
adoptive Treg cell therapy will necessitate further understanding 
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of factors that cause Tregs to lose FOXP3 expression and ways to 
stabilize its expression.
The question of how long transferred Tregs survive in  vivo 
is also of critical importance. It is understood that in order to 
establish long-term dominant tolerance, adoptively transferred 
Tregs must either survive and expand in the recipient, or be able 
to induce a tolerogenic phenotype on other T cells, a process 
known as infectious tolerance (144). It has been shown that some 
subpopulation of Tregs, such as those producing soluble factors, 
such as TGF-β (145), IL-10, and IL-35 (146), and the ongoing 
presence of recipient “infected” Tregs, are required to prevent 
allograft rejection (147, 148).
In the recent clinical trial of Treg therapy in hematopoietic 
stem cell transplantation, the transferred cells were no longer 
detected in the circulation after 2 weeks (56). Moreover, in the 
pediatric trial of Treg therapy in Type-I diabetes, infusion of 
30 ×  106/kg polyclonally expanded Tregs resulted in doubling 
of the percentage of circulating Tregs and a trend of increase at 
2 weeks (118). In these trials, it is not known whether the cells 
migrated to tissues or died. In this regard, we have recently 
used single photon emission computed tomography to image 
adoptively transferred Tregs in mice and reported that 24 h after 
intravenous injection, the cells were primarily localized in the 
spleen (149).
Therefore, to maximize the efficacy of Treg therapy, efforts will 
need to focus on finding ways to support the in  vivo survival, 
engraftment, and function of the infused Tregs. Since Tregs 
depend on exogenous IL-2 for survival, a suggested approach has 
been to use low-dose IL-2, which lacks the toxicity and immu-
nostimulatory effects of the higher IL-2 doses used to treat cancer 
patients (150). This approach has recently shown to increase the 
number of Tregs in patients with chronic GvHD (151), support-
ing the notion that low-dose IL-2 may be an ideal adjuvant to 
adoptive Treg cell therapy, by promoting Treg expansion in an 
otherwise inflammatory setting.
The future will also see studies defining the trafficking patterns 
of infused Tregs in vivo. In this regard, in a recent clinical trial 
of Treg immunotherapy in Type-I diabetes conducted at UCSF, 
Tregs were labeled with deuterium and their relative homing and 
survival period was recorded in vivo (Bluestone et al. unpublished 
data). In parallel, micro-PET computed tomography fusion has 
been used clinically to track infused T cells in the body and has 
further been refined to focus on distinct T cell populations, in 
particular Tregs (152). While these technologies are relatively 
new, the information gleaned from their inclusion in clinical 
trial protocols of Treg cell therapy will be invaluable, allowing for 
virtual visualization of these cells in vivo.
The future of cell therapy is also moving in such a way through 
cellular engineering, introducing concepts of traceable markers, 
tunable TCRs, chemotactic receptors to synthetic ligands, and 
drug inducible suicidal enzymes (153). These designer features 
would not only allow for the monitoring of infused Tregs, while 
also controlling their activities and trafficking patterns, but also 
for elimination if and when they become pathogenic (154, 155). 
Nonetheless, further advances in gene therapy would be required 
for these approaches to move forward, with licensing issues 
posing their own challenges and hurdles.
Dose of Regulatory T Cells, Number Of 
injections, and Monitoring Outcomes
As in the ThRIL trial, the first trials of Treg therapy in solid-organ 
transplantation have started with a dose escalation study to assess 
the safety and tolerability of Tregs at various doses. It is antici-
pated that high Treg doses are needed for tolerance induction in 
view of pre-clinical studies in mouse models of transplantation 
where a high ratio of Tregs to Teffectors, in the order of 1:1–1:2, 
i.e., 33–50% of Tregs, is needed to prevent transplant rejection 
(29, 156). Moreover, it has been suggested that, combined with 
ATG induction, a single infusion of 3–5 × 109 Tregs can effectively 
increase Treg percentage to more than 33% (157). One caveat is 
the use of antigen-specific Tregs, where studies have shown that 
lower numbers are needed to achieve the same functional efficacy 
as larger numbers of polyclonal Tregs (158, 159). Irrespectively, 
producing such large numbers of Tregs remains technically chal-
lenging, especially in view of studies showing a loss of FOXP3 
expression after several rounds of stimulation. In this regard, 
more research is needed to understand Treg commitment and 
epigenetic regulation of FOXP3 expression so that the mecha-
nisms can be harnessed to stabilize the Tregs.
Another point of consideration is if a single injection of Tregs 
is sufficient or whether multiple injections are required. This may 
be determined in larger Phase II efficacy studies, where patient 
outcomes should also be measured and an in-depth patient moni-
toring system planned. In this regard, molecular diagnostic tools 
can be utilized to assess a broad panel of biomarkers, associated 
with operational tolerance, to serve as surrogate end-points of 
efficacy (160–162).
In this regard, high-throughput, highly sensitive flow cyto-
metric analysis can also be used to determine if the number of 
Tregs in the peripheral blood of recipients have increased or 
relatively quantify the composition of the T cell compartment fol-
lowing the intervention (163). Furthermore, the cytokine profile 
secretion capacity of these cells can be analyzed and thus their 
plasticity evaluated. Investigations using the complementarity-
determining region 3 (CDR3) length distribution analysis can 
be used to explore the diversity of the TCR, in view of studies 
suggesting that the TCR repertoire might be a good predictor 
of graft outcome. In this regard, it has been suggested that the 
majority of kidney transplant patients with chronic rejection have 
an accumulation of oligo or monoclonal Vβ expansions while 
operationally tolerant recipients have a TCR repertoire like that 
of healthy individuals (164).
As such, a comprehensive immune monitoring plan of patients 
should be an integral part of a Treg therapy trial in order to gain 
mechanistic insight on the Treg function in patients. In addition, 
success in defining optimal ways of measuring tolerance would 
set the scene for subsequent trials in which accelerated drug 
minimization is the principal aim.
Anticipated Cost and the Future
At present, the cost to manufacture a single “personalized” 
injection of Tregs in the CRF is over £20,000 in the UK. The 
data soon emerging on the safety of these cells in the setting of 
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transplantation will provide the basis for progression to a larger 
Phase II/III study. The future progression of the cell therapy 
program will also see efforts focused on the optimization of the 
process development and potential commercialization of the cell-
based therapies, through collaborations with industry and other 
organizations. It is anticipated that the future optimization of the 
manufacturing process for larger scale trials and commercializa-
tion would reduce the costs, making this modality of treatment 
broadly available and applicable in other disease settings.
Conclusion
We are now entering an exciting era in the study of immunological 
tolerance. Several cellular and molecular strategies of tolerance 
induction have been developed in non-human transplant models 
that have shown considerable promise and are just now appearing 
in clinical trials. As such, the recent progress in Treg biology and 
the successes in the clinical grade manufacture of these cells has 
seen the start of clinical trials of Treg therapy in solid-organ trans-
plantation. Such trials will provide the basis for progression to a 
larger Phase II/III study with a comprehensive patient immune 
monitoring plan and the use of biomarkers that can predict the 
successful induction of immune tolerance, allowing for the safe 
minimization/withdrawal of immunosuppression. With this all 
said, it is no secret that the panacea of immunological tolerance 
in transplantation is now ordained as we take steps ever closer to 
its fulfilment.
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